1CP
XENE icon

17 Capital Partners’s Xenon Pharmaceuticals XENE Stock Holding History

17 Capital Partners’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,840
Closed -$392K – 137
2024
Q1 		$392K Buy
+2,840
New +$131K 0.29% 88

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

17 Capital Partners's XENE Position: Q2 2024 in Review

17 Capital Partners sold out of Xenon Pharmaceuticals (XENE) in Q2 2024, closing a stake of 2,840 shares — an estimated $392K sold.

17 Capital Partners first reported a position in XENE in Q1 2024 and held it in 1 quarter. The position peaked at $392K in Q1 2024. 213 funds tracked by Wall St. Rank hold XENE as of Q2 2024.

  • 17 Capital Partners reported no remaining Xenon Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
  • 17 Capital Partners sold 2,840 Xenon Pharmaceuticals shares in Q2 2024, an estimated $392K.
  • 17 Capital Partners first reported a position in Xenon Pharmaceuticals in Q1 2024 and held it in 1 quarter.
  • 17 Capital Partners's Xenon Pharmaceuticals position peaked at $392K in Q1 2024.
  • 213 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2024.

Based on 17 Capital Partners's 13F filing for Q2 2024, filed 18 Jul 2024.